The US Supreme Court is set to decide whether to limit access to a widely used abortion pill, marking a significant case on reproductive rights. This comes after the court overturned Roe v Wade, ending nationwide abortion rights. The Biden administration sought to reverse a decision restricting the drug mifepristone due to safety concerns raised by anti-abortion groups.
Mifepristone, legal in the US since 2000 and deemed safe by research, faces scrutiny in a case initiated by anti-abortion doctors and activists in Texas, claiming FDA approval was unlawful. The Supreme Court, with a 6-3 conservative majority, will hear arguments early next year, with a ruling expected before the next presidential election.
This clash on access follows the court’s 2022 decision against Roe v Wade, prompting states to either ban or limit abortion. Medication abortions, now the most common, are at the center of this battle. The FDA approved the two-drug regimen in 2000, and since 2016, eased access via telemedicine and mail prescriptions.
Despite FDA, ACOG, and mainstream medical organizations affirming safety, anti-abortion groups argue against medication abortion.
In April, a Texas judge imposed a nationwide ban, later partially lifted by an appeals court.
The Supreme Court now considers whether to uphold recent restrictions, potentially requiring in-person prescriptions.
While the court won’t revisit FDA approval, the decision could impact abortion access, especially in restricted states.
Pro-choice groups applaud reviewing “erroneous” restrictions, emphasizing over 20 years of safe abortion pill use.
Anti-abortion groups see an opportunity to highlight perceived dangers.
US studies show medication abortion’s effectiveness at about 95%, with minimal follow-up chances.
Deaths linked to mifepristone are fewer than common antibiotics. The court’s decision may not only affect abortion but also influence the FDA’s drug approval process, raising concerns about broader implications for medical research and development.
The court’s decision could have major implications for other FDA-approved drugs as well, Carl Tobias, a law professor at the University of Richmond, said.
“The plaintiffs’ efforts potentially implicate the entire FDA new drug application process, which could undermine research and development of new drugs that save lives and reduce pain,” he said.
